About Bile acid-CoA:amino acid N-acyltransferase
Bile acid-CoA:amino acid N-acyltransferase (BAAT) is a protein
from Homo sapiens identified by UniProt accession
Q14032, 418 residues long.
MolForge cross-references it against 0 known binders and
98 disease associations.
Target properties
| Protein name | Bile acid-CoA:amino acid N-acyltransferase |
| UniProt accession | Q14032 |
| Gene | BAAT |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (98)
Diseases linked to this target (Open Targets).
- hypercholanemia, familial · score 0.67
- bile acid conjugation defect 1 · score 0.65
- Cholestasis · score 0.46
- cholestasis · score 0.46
- C-reactive protein measurement · score 0.27
- hypercholanemia, familial 1 · score 0.19
- cutaneous melanoma · score 0.15
- protein measurement · score 0.06
- dehydrated hereditary stomatocytosis · score 0.04
- Familial hemophagocytic lymphohistiocytosis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14032-F1 | alphafold | PREDICTED | 95.17 | — |
Amino-acid sequence (418 residues)
MIQLTATPVS ALVDEPVHIR ATGLIPFQMV SFQASLEDEN GDMFYSQAHY RANEFGEVDL NHASSLGGDY MGVHPMGLFW SLKPEKLLTR LLKRDVMNRP FQVQVKLYDL ELIVNNKVAS APKASLTLER WYVAPGVTRI KVREGRLRGA LFLPPGEGLF PGVIDLFGGL GGLLEFRASL LASRGFASLA LAYHNYEDLP RKPEVTDLEY FEEAANFLLR HPKVFGSGVG VVSVCQGVQI GLSMAIYLKQ VTATVLINGT NFPFGIPQVY HGQIHQPLPH SAQLISTNAL GLLELYRTFE TTQVGASQYL FPIEEAQGQF LFIVGEGDKT INSKAHAEQA IGQLKRHGKN NWTLLSYPGA GHLIEPPYSP LCCASTTHDL RLHWGGEVIP HAAAQEHAWK EIQRFLRKHL IPDVTSQL
Explore Bile acid-CoA:amino acid N-acyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets